SCHEMBL19486307

SCHEMBL19486307

CCCCOc1ccc(C(=N)N)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.49
F10 P00742 1/20 0.49
PLAU P00749 1/20 0.49
PLAT P00750 1/20 0.49
MAOB P27338 8/20 0.49
LTA4H P09960 2/20 0.49
NR5A1 Q13285 1/20 0.49
PPARD Q03181 1/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PRSS1 P07477 3/20 0.46
TMPRSS2 O15393 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486302 0.94 F2 (0.49) F2F10PLAUPLATMAOB
SCHEMBL15149837 0.85 PRSS1 (0.44) F2F10PLAUPLATMAOB
SCHEMBL19486226 0.84 THRA (0.51) F2F10PLAUGAARAB9A
SCHEMBL15145194 0.84 PRSS1 (0.47) F2F10PLAUPLATMAOB
SCHEMBL19481642 0.83 F2 (0.43) F2F10PLAUPLATMAOB
SCHEMBL3296026 0.80 NR5A1 (0.57) MAOBLTA4HNR5A1PPARDMEN1
SCHEMBL1116272 0.80 NPC1 (0.61) MAOBLTA4HNR5A1PPARDMEN1
SCHEMBL30084742 0.80 NPC1 (0.61) MAOBLTA4HNR5A1PPARDMEN1
SCHEMBL9170910 0.79 PRMT1 (0.47) F2F10PLAUNR5A1NPC1
SCHEMBL16450867 0.79 PLAU (0.45) F2F10PLAUPLATMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148439-A1 DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N-SULFATED BETA LACTAMS ARIXA PHARMACEUTICALS, INC. 2018-05-31 US disclosed
US-20170298057-A1 DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS ARIXA PHARMACEUTICALS, INC. 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298057-A1 DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N- SULFATED BETA LACTAMS DDOST, LBR, STS F2 1548/4885F10 3332/4885PLAU 1445/4885
US-20180148439-A1 DEUTERATED O-SULFATED BETA LACTAM HYDROXAMIC ACIDS AND DEUTERATED N-SULFATED BETA LACTAMS DDOST, LBR, STS F2 1548/4885F10 3332/4885PLAU 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.